NCT02866149: ALCINA

Analysis of Circulating Tumor Markers in the Blood

Completed NA Last updated 27 September 2024

What this trial tests

NA trial testing Blood sampling in Cancer in 682 participants. Completed in 1 September 2024.

Timeline

1 July 2015

Primary endpoint
1 July 2024

1 September 2024

Quick facts

Lead sponsor	Institut Curie
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	682
Start date	1 July 2015
Primary completion	1 July 2024
Estimated completion	1 September 2024
Sites	5 locations across France

Drugs / interventions tested

• Blood sampling — full drug profile →
• Tumor sampling
• Stool sampling — full drug profile →

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Feasibility of the analysis of different blood-borne tumor biomarkers
  Time frame: 18 months
  Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients ".

Sponsor's own description

Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.
   Rodrigues M, Mobuchon L, Houy A, Fiévet A, et al · · 2018 · cited 104× · PMID 29760383 · DOI 10.1038/s41467-018-04322-5
2. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
   Sinoquet L, Jacot W, Gauthier L, Pouderoux S, et al · · 2021 · cited 56× · PMID 34355741 · DOI 10.1093/clinchem/hvab131
3. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
   Darrigues L, Pierga JY, Bernard-Tessier A, Bièche I, et al · · 2021 · cited 55× · PMID 33676547 · DOI 10.1186/s13058-021-01411-0
4. Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade.
   Eslami-S Z, Cortés-Hernández LE, Thomas F, Pantel K, et al · · 2022 · cited 52× · PMID 35484215 · DOI 10.1038/s41416-022-01819-1
5. Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation.
   Pantel K, Alix-Panabières C. · · 2022 · cited 47× · PMID 36517082 · DOI 10.1136/jitc-2022-005615
6. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
   Jacot W, Mazel M, Mollevi C, Pouderoux S, et al · · 2020 · cited 42× · PMID 32712650 · DOI 10.1093/clinchem/hvaa121
7. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
   Shields MD, Chen K, Dutcher G, Patel I, et al · · 2022 · cited 34× · PMID 36012272 · DOI 10.3390/ijms23169006
8. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
   Eslami-S Z, Cortés-Hernández LE, Sinoquet L, Gauthier L, et al · · 2024 · cited 30× · PMID 37973956 · DOI 10.1038/s41416-023-02491-9